- Guardant Health ( NASDAQ: GH ) has expanded an existing agreement with Merck KGaA ( OTCPK:MKGAF )( OTCPK:MKKGY ) on the development of precision cancer therapeutics to focus on core cancer indications with significant unmet need.
- Merck KGaA ( OTCPK:MKGAF )( OTCPK:MKKGY ) will work with Guardant Health ( GH ) data scientists to utilize genomics and clinical information from the GuardantINFORM platform.
- The platform combines de-identified longitudinal clinical information and genomic data collected from the Guardant360 liquid biopsy test. It contains data from more than 225K cancer patients.
- Seeking Alpha's Quant Rating views Guardant Health ( GH ) as a sell.
For further details see:
Guardant Health expands collaboration with Merck KGaA on precision oncology therapies